Pfizer [PFE] vs Gilead Sciences [GILD] Detailed Stock Comparison

Pfizer Inc.

NYSE
Loading...

Gilead Sciences, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Pfizer Inc. wins in 9 metrics, Gilead Sciences, Inc. wins in 12 metrics, with 0 ties. Gilead Sciences, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pfizer Inc. Gilead Sciences, Inc. Better
P/E Ratio (TTM) 19.61 19.66 Pfizer Inc.
Price-to-Book Ratio 1.75 7.29 Pfizer Inc.
Debt-to-Equity Ratio 77.96 112.92 Pfizer Inc.
PEG Ratio -0.04 0.85 Gilead Sciences, Inc.
EV/EBITDA 8.01 12.44 Pfizer Inc.
Profit Margin (TTM) 12.42% 28.90% Gilead Sciences, Inc.
Operating Margin (TTM) 23.95% 37.38% Gilead Sciences, Inc.
EBITDA Margin (TTM) 23.95% 37.38% Gilead Sciences, Inc.
Return on Equity 8.89% 40.66% Gilead Sciences, Inc.
Return on Assets (TTM) 5.68% 12.52% Gilead Sciences, Inc.
Free Cash Flow (TTM) $9.08B $9.46B Gilead Sciences, Inc.
Dividend Yield 6.71% 2.57% Pfizer Inc.
1-Year Return 6.81% 14.19% Gilead Sciences, Inc.
Price-to-Sales Ratio (TTM) 2.42 5.62 Pfizer Inc.
Enterprise Value $206.00B $181.31B Pfizer Inc.
EV/Revenue Ratio 3.29 6.16 Pfizer Inc.
Gross Profit Margin (TTM) 69.97% 79.51% Gilead Sciences, Inc.
Revenue per Share (TTM) $11 $24 Gilead Sciences, Inc.
Earnings per Share (Diluted) $1.36 $6.78 Gilead Sciences, Inc.
Beta (Stock Volatility) 0.39 0.40 Pfizer Inc.
Short % of Float 2.33% 1.74% Gilead Sciences, Inc.

Pfizer Inc. vs Gilead Sciences, Inc. Stock Performance Analysis

Loading Price Chart...

PFE
GILD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pfizer Inc.-0.80%1.48%2.65%-2.29%-1.63%3.26%
Gilead Sciences, Inc.-1.03%-2.97%-4.07%-14.40%3.77%2.22%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pfizer Inc.6.81%-34.57%-32.47%-19.28%36.37%17.90%
Gilead Sciences, Inc.14.19%59.26%88.55%51.95%535.26%767.93%

Performance & Financial Health Analysis: Pfizer Inc. vs Gilead Sciences, Inc.

MetricPFEGILD
Market Information
Market Cap i$153.59B$165.87B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i30,662,9314,914,212
90 Day Avg. Volume i36,790,7555,711,564
Last Close$26.00$124.30
52 Week Range$23.11 - $28.75$104.46 - $157.29
% from 52W High-9.57%-20.97%
All-Time High$61.71 (Dec 20, 2021)$157.27 (Feb 11, 2026)
% from All-Time High-57.87%-20.96%
Growth Metrics
Quarterly Revenue Growth-0.01%0.05%
Quarterly Earnings Growth-0.01%0.22%
Financial Health
Profit Margin (TTM) i0.12%0.29%
Operating Margin (TTM) i0.24%0.37%
Return on Equity (TTM) i0.09%0.41%
Debt to Equity (MRQ) i77.96112.92
Cash & Liquidity
Book Value per Share (MRQ)$15.21$18.29
Cash per Share (MRQ)$2.39$7.74
Operating Cash Flow (TTM) i$11.70B$10.02B
Levered Free Cash Flow (TTM) i$13.43B$7.54B
Dividends
Last 12-Month Dividend Yield i6.71%2.57%
Last 12-Month Dividend i$1.72$3.98

Valuation & Enterprise Metrics Analysis: Pfizer Inc. vs Gilead Sciences, Inc.

MetricPFE (Apr 26, 2026)GILD (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i19.6119.66
Forward P/E i9.4813.85
PEG Ratio i-0.040.85
Price to Sales (TTM) i2.425.62
Price to Book (MRQ) i1.757.29
Market Capitalization
Market Capitalization i$153.59B$165.87B
Enterprise Value i$206.00B$181.31B
Enterprise Value Metrics
Enterprise to Revenue i3.296.16
Enterprise to EBITDA i8.0112.44
Risk & Other Metrics
Beta i0.390.40
Book Value per Share (MRQ) i$15.21$18.29

Financial Statements Comparison: Pfizer Inc. vs Gilead Sciences, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPFE (2025)GILD (2025)
Revenue/Sales i62.58B29.44B
Cost of Goods Sold i16.07B6.23B
COGS % of Revenue i25.7%21.2%
Gross Profit i46.51B23.21B
Gross Margin i74.3%78.8%
Research & Development i10.44B5.80B
Operating Income (EBIT) i17.41B11.70B
Operating Margin i27.8%39.7%
EBITDA i25.75B14.81B
EBITDA Margin i41.1%50.3%
Pre-Tax Income i7.52B9.80B
Pre-Tax Income % of Revenue i12.0%33.3%
Income Tax i-266.00M1.29B
Income Tax % of Revenue i-0.4%4.4%
Net Income (Profit) i7.81B8.51B
Profit Margin i12.5%28.9%

Balance Sheet & Liquidity Metrics

MetricPFE (2025)GILD (2025)
Cash & Equivalents i1.14B7.56B
Total Current Assets i42.90B18.34B
Total Current Assets % of Revenue i68.6%62.3%
Total Current Liabilities i36.98B11.81B
Total Current Liabilities % of Revenue i59.1%40.1%
Long-Term Debt i60.81B22.13B
Long-Term Debt % of Revenue i97.2%75.2%
Total Shareholders Equity i86.78B22.62B
Retained Earnings i114.61B13.73B
Retained Earnings % of Revenue i183.1%46.6%
Property, Plant & Equipment i01.71B

Cash Flow Statement Comparison

MetricPFE (2025)GILD (2025)
Operating Cash Flow i6.43B10.19B
Operating Cash Flow % of Revenue i10.3%34.6%
Capital Expenditures i-2.63B-563.00M
Free Cash Flow i9.08B9.46B
FCF Margin i14.5%32.1%
Debt Repayment i-9.75B-1.79B
Common Stock Repurchase iN/A-1.92B

Short Interest & Institutional Ownership Analysis

MetricPFEGILD
Shares Short i132.47M21.52M
Short Ratio i3.173.56
Short % of Float i2.33%1.74%
Shares Outstanding i5.69B1.24B
Float Shares i5.68B1.24B
% Held by Insiders i0.10%0.13%
% Held by Institutions i68.38%92.71%
% Held by Public i31.52%7.16%

Dividend Analysis & Yield Comparison: Pfizer Inc. vs Gilead Sciences, Inc.

MetricPFEGILD
Last 12-Month Dividend i$1.72$3.98
Last 12-Month Dividend Yield i6.71%2.57%
3-Year Avg Annual Dividend i$1.69$3.35
3-Year Avg Dividend Yield i1.54%0.85%
3-Year Total Dividends i$5.06$10.06
Ex-Dividend DateJan 23, 2026Mar 13, 2026